This product is for laboratory research and has not been approved by the FDA for human use. RU-58841 is NOT a dietary supplement. Any information about its use in this product description refers to clinical research only. By ordering from this site, you agree to our terms of service.
RU-58841 is a non-steroidal anti-androgen that acts as a competitive androgen receptor antagonist. Originally developed for the treatment of androgen-dependent conditions, RU-58841 is widely used as a research compound for studying localized androgen receptor inhibition, particularly in dermatological and hair follicle biology research.
RU-58841 is a synthetic anti-androgen compound originally developed by Roussel Uclaf (now part of Sanofi) in the 1970s for research into androgen-dependent skin conditions. As a selective androgen receptor antagonist, RU-58841 binds to androgen receptors and blocks the action of androgens like testosterone and dihydrotestosterone (DHT) at the tissue level
Unlike systemic anti-androgens, RU-58841 was designed for topical application, allowing researchers to study localized androgen receptor blockade without affecting systemic hormone levels. This tissue-selective approach makes it particularly valuable for investigating androgen-mediated processes in skin and hair follicles.
RU-58841 Name and Classification
RU-58841 is identified by its research designation and is classified as a non-steroidal anti-androgen. The compound is also known by its chemical name PSK-3841 or HMR-3841 in some scientific literature.
RU-58841 belongs to a class of compounds designed to competitively inhibit androgen receptors without activating them, distinguishing it from both androgens and selective androgen receptor modulators (SARMs). The compound was originally investigated for potential therapeutic applications in androgenetic alopecia and acne.
Mechanism of Action
RU-58841 functions as a competitive androgen receptor antagonist, binding to androgen receptors in target tissues and preventing endogenous androgens from activating these receptors.
Key mechanistic features include:
- Competitive inhibition of androgen receptor binding by testosterone and DHT
- Topical application allows localized action at the site of administration
- Minimal systemic absorption when applied topically, reducing whole-body hormonal effects
- Selective tissue targeting enables study of androgen effects in specific areas
In experimental models, RU-58841 demonstrates the ability to block androgen-mediated signaling in hair follicles and sebaceous glands while maintaining negligible systemic anti-androgenic activity when applied topically. This allows researchers to isolate and study androgen receptor function in specific tissues.
Benefits in Research
In preclinical research settings, RU-58841 has been studied for its effects on androgen-responsive tissues, particularly hair follicles and skin. Published animal and in vitro studies suggest that RU-58841 may:
- Block androgen receptor activation in hair follicles
- Prevent DHT-mediated miniaturization of hair follicles in experimental models
- Inhibit sebaceous gland activity influenced by androgens
- Provide localized anti-androgenic effects without systemic hormone suppression
- Enable study of tissue-specific androgen receptor signaling
These findings from controlled experimental models help researchers understand the role of androgens in hair biology, skin physiology, and androgen-responsive tissue function.
RU-58841 Dosage in Experimental Studies
Most available data on RU-58841 dosage comes from preclinical topical application studies. Published research reports varying protocols depending on the experimental model and research objectives.
Typical experimental dosing approaches:
- Topical application concentrations ranging from 2.5% to 5% in solution form
- Vehicle solutions commonly include ethanol, propylene glycol, or other dermal penetration enhancers
- Application frequency typically once or twice daily in animal studies
- Application area generally limited to specific test sites for localized effect assessment
Dosing considerations in research:
- Concentration and vehicle composition affect dermal absorption
- Application volume and frequency influence local tissue exposure
- Duration of treatment varies from acute (single application) to chronic (several weeks)
- Systemic absorption is minimal with topical application in most experimental protocols
The RU-58841 dosage and formulation used in research directly impact local tissue concentrations and the degree of androgen receptor blockade achieved, making formulation design a critical component of experimental protocols.
RU-58841 vs Finasteride – Comparative Research
RU-58841 vs finasteride represents two distinct approaches to androgen modulation in research. Understanding their mechanistic differences is important for experimental design.
Mechanism comparison:
RU-58841c:
- Acts as an androgen receptor antagonist
- Blocks androgen receptors directly in target tissues
- Applied topically for localized effects
- Does not affect systemic DHT or testosterone levels
Finasteride:
- Acts as a 5-alpha reductase inhibitor
- Prevents conversion of testosterone to DHT systemically
- Administered orally with whole-body effects
- Reduces circulating DHT levels throughout the body
Research application differences:
RU-58841:
- Used to study localized androgen receptor blockade
- Allows investigation of tissue-specific androgen effects
- Minimal systemic hormonal impact in topical studies
- Suitable for dermatological and hair follicle research
Finasteride:
- Used to study systemic DHT reduction effects
- Affects DHT-dependent processes throughout the body
- Impacts systemic hormone levels
- Broader endocrine research applications
The RU-58841 vs finasteride comparison highlights different research approaches: direct receptor blockade versus enzymatic inhibition of androgen synthesis. Both compounds serve distinct purposes in androgen-related research, with RU-58841 offering advantages for localized tissue studies.
RU-58841 Side Effects in Research Models
Because RU-58841 is designed for topical application with minimal systemic absorption, RU-58841 side effects observed in research differ from systemic anti-androgens. In preclinical studies, researchers monitor for:
Topical application site effects:
- Skin irritation or sensitivity at application sites
- Dermatological reactions to vehicle components
- Local inflammatory responses in some experimental protocols
- Dryness or scaling in application areas
Systemic observations:
- Minimal systemic anti-androgenic effects when applied topically as designed
- Negligible impact on circulating hormone levels in most topical application studies
- No significant suppression of testosterone or DHT in properly conducted topical experiments
Experimental considerations:
- Vehicle composition can influence irritation profiles
- Application concentration affects local tolerability
- Individual variability in dermal absorption exists in animal models
Understanding these RU-58841 side effects helps researchers design appropriate topical formulations and establish safe concentration parameters for experimental use. The localized nature of topical application generally limits systemic effects in research models.
Topical Administration in Research
RU-58841 is administered topically in research settings, typically dissolved in alcohol-based or propylene glycol-based solutions. This route of administration allows researchers to:
- Achieve localized androgen receptor blockade in specific tissue areas
- Minimize systemic exposure and whole-body hormonal effects
- Study tissue-specific responses to androgen receptor antagonism
- Evaluate formulation effects on dermal penetration and local bioavailability
The topical route is central to RU-58841's experimental utility, as it enables investigation of androgen receptor function in skin and hair follicles without the confounding effects of systemic anti-androgen activity.
Human Clinical Trials
RU-58841 was evaluated in early-phase human clinical trials in the 1990s and early 2000s for androgenetic alopecia. While initial results showed promise for localized anti-androgenic effects, the compound was not advanced to market approval. Development was discontinued, and detailed clinical trial data remains limited in public literature.
Current research remains primarily preclinical, focused on understanding RU-58841's mechanisms and potential applications at the molecular and tissue level.
Why You Should Buy RU-58841 from Sarmful
If you are looking to buy RU-58841 for research purposes, Sarmful offers RU-58841 for sale in powder form, prepared to support consistent and reliable experimental formulation work.
When you buy RU-58841 from Sarmful, you benefit from:
- Third-party lab testing and in-house verification for purity and concentration
- EU and US domestic shipping for reliable delivery to your research facility
- Convenient payment methods designed for seamless research procurement
- Research-grade quality formulated to meet the standards of serious laboratory work
RU-58841 is available for sale exclusively for legitimate research applications. All products are intended for in vitro research and laboratory experimentation only, not for human consumption or personal use.
Reviews
There are no reviews yet.